ArticleInternational journal of cancer2021
Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
Open access · hybridAbstract read
In one paragraph
Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.Signal transduction and targeted therapy · 2023Pooled it
- Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.BMC medicine · 2022Pooled it
- Blood-based obesity biomarkers and their relevance for disease risk.Nature reviews. Endocrinology · 2026Review
- Adiposity and cancer: epidemiology, mechanisms and future perspectives.Nature metabolism · 2026Review
- Evaluating the causal role of LEPR signaling in 16 cancers: A drug-target Mendelian randomization study.Medicine · 2026Article
- Evaluating plasma adipokines and their cognate receptors as biomarkers for non-invasive diagnosis of endometrial cancer.Bioscience reports · 2025Article
- Impact of Adipokine Expression on Tumor Characteristics and Survival Outcomes in Patients with Renal Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Genetically proxied risk and protective factors for pancreatic cancer: a systematic review and meta-analysis of Mendelian randomization studies.Journal of gastrointestinal oncology · 2025Article
- PAI-1 uncouples integrin-β1 from restrain by membrane-bound β-catenin to promote collagen fibril remodeling in obesity-related neoplasms.Cell reports · 2024Article
- Precision Nutrition Unveiled: Gene-Nutrient Interactions, Microbiota Dynamics, and Lifestyle Factors in Obesity Management.Nutrients · 2024Review
- The causal effects of genetically determined immune cells on gynecologic malignancies: a Mendelian randomization study.Frontiers in oncology · 2024Article
- [Associations of circulating leptin levels with colorectal adenoma and colorectal cancer: a case-control and Mendelian randomization study].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Adipokines in pulmonary hypertension: angels or demons?Heliyon · 2023Review
- Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms.Cancers · 2023Article
- Multi-trait genome-wide association study identifies a novel endometrial cancer risk locus that associates with testosterone levels.iScience · 2023Article
- Exploratory analysis of the effect of a controlled lifestyle intervention on inflammatory markers - the Healthy Lifestyle Community Programme (cohort 2).BMC nutrition · 2023Article
- The impact of obesity and adipokines on breast and gynecologic malignancies.Annals of the New York Academy of Sciences · 2022Review
- Role and mechanism of alpa1-antitrypsin in polycystic ovary syndrome.Saudi medical journal · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 7 countries.
Niki L DimouSection of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-1678-9328
Nikos PapadimitriouSection of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.
Daniela MariosaSection of Genetics, International Agency for Research on Cancer, Lyon, France.
Mattias JohanssonSection of Genetics, International Agency for Research on Cancer, Lyon, France.
Paul BrennanSection of Genetics, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-0518-8714
Ulrike PetersFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Mark PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
D Timothy BishopLeeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Manuela Gago-DominquezFundación Gallega de Medicina Genómica, Grupo de Genéticadel Cáncer, Instituto de Investigación Sanitaria de Santiago IDIS, Complejo Hospitalario Univ. Santiago-CHUS, SERGAS, Santiago de Compostela, Spain.ORCID 0000-0001-6713-4351
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Victor MorenoOncology Data Analytics Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-2818-5487
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0003-1226-070X
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5174-3769
Peter T CampbellBehavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia, USA.
Edward GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Yi LinPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
CCFR, Endometrial Cancer Association Consortium
Marc J GunterSection of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.
Neil MurphySection of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-3347-8249
Centre international de recherche sur le cancer · FRFred Hutch Cancer Center · USNational Institutes of Health · USAmerican Cancer Society · USBrigham and Women's Hospital · USInstitut d'Investigació Biomédica de Bellvitge · ESJohns Hopkins University · USThe University of Melbourne · AUThe University of Texas MD Anderson Cancer Center · USUniversity of California San Diego · USUniversity of Leeds · GBUppsala University · SEVanderbilt University · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MTranslational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MSWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MValidity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI RIMM, ERIC B · 1991 to 2009
$41.8MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2MUNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian Michael Carroll · 1999 to 2026
$31.6MPILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Temitope O. Keku · 1985 to 2026
$30.5MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MStatistical Methods for Integrative Genomics in CancerP01CA196569 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul Marjoram · 2016 to 2026
$25.5MCancer Research UK 10589Cancer Research UK 14136Cancer Research UK 19167Cancer Research UK C490/A16561Cancer Research UK C570/A16491Cancer Research UK C588/A19167Cancer Research UK C8221/A19170Department of HealthMedical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCATS NIH HHS KL2 TR000421NCI NIH HHS HHSN261201500005CNCI NIH HHS K05 CA152715NCI NIH HHS K05 CA154337NCI NIH HHS K07 CA190673NCI NIH HHS P01 CA033619NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA196569NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA059045NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA066635NCI NIH HHS R01 CA076366NCI NIH HHS R01 CA097325NCI NIH HHS R01 CA136726NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA197350NCI NIH HHS R01 CA201407NCI NIH HHS R01 CA207371NCI NIH HHS R03 CA153323NCI NIH HHS R21 CA191312NCI NIH HHS R35 CA197735NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA164930NCI NIH HHS U01 CA167551NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA182883NCI NIH HHS U01 CA206110NCI NIH HHS U19 CA148107NCI NIH HHS U24 CA074783NCI NIH HHS U24 CA074794NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA182883NCI NIH HHS UM1 CA186107NCI NIH HHS Z01 CP010200NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01 HG004446NHLBI NIH HHS HHSN268201100046CNHLBI NIH HHS HHSN268201200008INIA NIH HHS HHSN271201100004CNIDDK NIH HHS P30 DK034987NIDDK NIH HHS P30 DK056350NIDDK NIH HHS P30 DK058404NIEHS NIH HHS T32 ES013678WHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004CWorld Health Organization 001
Abstract
Obesity is considered a chronic inflammatory state characterized by continued secretion of adipokines and cytokines. Experimental and epidemiological evidence indicates that circulating adipokines may be associated with the development of obesity-related cancers, but it is unclear if these associations are causal or confounded. We examined potential causal associations of specific adipokines (adiponectin, leptin, soluble leptin receptor [sOB-R] and plasminogen activator inhibitor-1 [PAI-1]) with five obesity-related cancers (colorectal, pancreatic, renal cell carcinoma [RCC], ovarian and endometrial) using Mendelian randomization (MR) methods. We used summary-level data from large genetic consortia for 114 530 cancer cases and 245 284 controls. We constructed genetic instruments using 18 genetic variants for adiponectin, 2 for leptin and 4 for both sOB-R and PAI-1 (P value for inclusion<5 × 10
Indexed as
AdipokinesAdiponectinBody Mass IndexCarcinoma, Renal CellColorectal NeoplasmsCorrelation of DataEndometrial NeoplasmsFemaleGenome-Wide Association StudyHumansLeptinMendelian Randomization AnalysisObesityOvarian NeoplasmsPancreatic NeoplasmsPlasminogen Activator Inhibitor 1AdipokinesAdiponectinLEPR protein, humanLeptinPlasminogen Activator Inhibitor 1Receptors, LeptinSERPINE1 protein, humanadiponectincancerleptinMendelian randomizationplasminogen activator inhibitorsoluble leptin receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.